Leader M, Patel J, Collins M, Henry K
Department of Histopathology, Charing Cross and Westminster Medical School, London, UK.
Br J Cancer. 1989 Jan;59(1):106-9. doi: 10.1038/bjc.1989.21.
Tumour markers now have an established role in tumour diagnosis and patient management. However, antibodies used to detect these tumour markers have in some instances proved unreliable, with a low rate of sensitivity and specificity. In this study we wished to evaluate the role of a commercial antibody to myoglobin as a marker of rhabdomyosarcomas. The purpose of this investigation was to assess the sensitivity and specificity of myoglobin antiserum as a marker of rhabdomyosarcomas. This was performed by reacting a large number of tumours (sarcomas, carcinomas and melanomas) with a polyclonal anti human myoglobin antiserum. Staining was demonstrated in 60% of rhabdomyosarcomas. Only two tumours from a total of 226 non-skeletal muscle tumours showed a positive reaction (0.88%). One was a leiomyosarcoma and the other had been classified as an undifferentiated sarcoma but a rhabdomyosarcoma was included in its differential diagnosis. It is of interest that both had been earlier irradiated. This antiserum was therefore a specific but not a very sensitive tumor marker. Its rate of staining of rhabdomyosarcomas is compared with the results in the literature. A great disparity is found and the reasons for this are discussed.
肿瘤标志物目前在肿瘤诊断和患者管理中已确立了其作用。然而，用于检测这些肿瘤标志物的抗体在某些情况下已被证明不可靠，其敏感性和特异性较低。在本研究中，我们希望评估一种商用肌红蛋白抗体作为横纹肌肉瘤标志物的作用。本调查的目的是评估肌红蛋白抗血清作为横纹肌肉瘤标志物的敏感性和特异性。这是通过使大量肿瘤（肉瘤、癌和黑色素瘤）与多克隆抗人肌红蛋白抗血清反应来进行的。在60%的横纹肌肉瘤中观察到染色。在总共226个非骨骼肌肿瘤中，只有两个肿瘤显示出阳性反应（0.88%）。一个是平滑肌肉瘤，另一个曾被归类为未分化肉瘤，但横纹肌肉瘤在其鉴别诊断中。有趣的是，两者都曾接受过早期放疗。因此，这种抗血清是一种特异性但不太敏感的肿瘤标志物。将其对横纹肌肉瘤的染色率与文献中的结果进行了比较。发现了很大的差异，并讨论了其原因。
